从脾虚湿盛论糖尿病与新型冠状病毒肺炎

相萍萍; 王旭; 刘超

从脾虚湿盛论糖尿病与新型冠状病毒肺炎

相萍萍^1,2,
王旭³,
刘超^1,2

1.
南京中医药大学附属中西医结合医院，江苏南京 210028
2.
江苏省中医药研究院，江苏南京 210028
3.
南京中医药大学第一临床医学院，江苏南京 210023

计量
- 文章访问数: 533
- HTML全文浏览量: 7
- PDF下载量: 476
- 被引次数: 0
出版历程
- 刊出日期: 2020-07-10

Discussion on Diabetes and the COVID-19 from the Perspective of Spleen Deficiency and Dampness Excess

1.
Jiangsu Integrated Chinese and Western Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210028, China
2.
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China
3.
The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China

摘要

摘要: 新型冠状病毒肺炎（COVID-19）是危害全球的流行性疾病。该文认为糖尿病与COVID-19存在共同的内源性基础脾虚，而湿邪不仅是疾病发展过程中的病理产物，也是致病的重要因素。糖尿病患者脾虚湿盛，卫气化生乏源，卫外不固，易感受病邪而患病；津液输布失常，水湿上渍于肺，合并COVID-19，痰湿上犯，可加重咳、痰、喘等症，增加其不良预后及死亡的风险，故脾虚湿盛是糖尿病患者易患COVID-19和病情加重的关键。
- 新型冠状病毒肺炎 /
- 糖尿病 /
- 脾虚湿盛
Abstract: COVID-19 is a global epidemic disease. This paper holds that diabetes and COVID-19 have a common endogenous basis for spleen deficiency. Besides， dampness is not only a pathological product in the course of disease development but also an important pathogenic factor. The clinical manifestations of diabetes patients are spleen deficiency and dampness excess， defensive qi lack of source， insecurity of defensive qi， susceptible to pathogenic factors， and then catch diseases， abnormal fluids transportation results in dampness invading lung. When diabetes patients caught COVID-19， the phlegm-dampness will attack the lung upward， which would aggravate symptoms such as cough， phlegm， and puff and increase the risk of poor prognosis and death. On this basis， spleen deficiency and dampness excess is the crucial factor for diabetes patients to catch COVID-19 and exacerbations.
- COVID-19 /
- diabetes /
- spleen deficiency and dampness excess

HTML全文

参考文献(23)

[1]	GUAN WJ， NI ZY， HU Y， et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med， 2020， 382(18):1708-1720.
[2]	WANG D， HU B， HU C， et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan， China[J]. JAMA， 2020， 323(11):1061-1069.
[3]	WU H， LAU ESH， MA RCW， et al. Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong， 2001-2016: A retrospective cohort study[J]. Diabetologia， 2020， 63(4):757-766.
[4]	KLEKOTKA RB， MIZGALA E， KROL W. The etiology of lower respiratory tract infections in people with diabetes[J]. Pneumonol Alergol Pol， 2015， 83(5):401-408.
[5]	HUANG C， WANG Y， LI X， et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan， China[J]. Lancet， 2020， 395(10223):497-506.
[6]	ZHOU F， YU T， DU R， et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan， China: A retrospective cohort study[J]. Lancet， 2020， 395(10229):1054-1062.
[7]	CHEN N， ZHOU M， DONG X， et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan， China: A descriptive study[J]. Lancet， 2020， 395(10223):507-513.
[8]	ALRADDADI BM， WATSON JT， ALMARASHI A， et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans， saudi arabia， 2014[J]. Emerg Infect Dis， 2016， 22(1):49-55.
[9]	YANG X， YU Y， XU J， et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan， China: A single-centered， retrospective， observational study[J]. Lancet Respir Med， 2020， 8(5):475-481.
[10]	DU Y， TU L， ZHU P， et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study[J]. Am J Respir Crit Care Med， 2020， 201(11):1372-1379.
[11]	KLONOFF DC， UMPIERREZ GE. COVID-19 in patients with diabetes: Risk factors that increase morbidity[J]. Metabolism， 2020， 108:154224.
[12]	GUO W， LI M， DONG Y， et al. Diabetes is a risk factor for the progression and prognosis of COVID-19[J]. Diabetes Metab Res Rev， 2020，2020: e3319.
[13]	张锡纯. 医学衷中参西录[M].石家庄:河北人民出版社，1957：158.
[14]	张文佳，付晓乐，辛效毅.2型糖尿病中医证型与临床生化指标的关系[J].南京中医药大学学报，2017，33(5):484-487.
[15]	灵枢经[M].北京:人民卫生出版社，2005:74.
[16]	刘杰民，蔺晓源，王敏，等.基于肠道黏膜免疫的“脾为之卫”理论探讨[J]. 中国中医基础医学杂志， 2013， 19(4):460-466.
[17]	张秉成.成方便读[M].北京:学苑出版社，2010：67-68.
[18]	仝小林，李修洋，赵林华，等.从“寒湿疫”角度探讨新型冠状病毒肺炎的中医药防治策略[J].中医杂志，2020，61(6):465-470，553.
[19]	周铭心.从五运六气辨识与防治新型冠状病毒肺炎[J].中医学报，2020，35(2):227-231.
[20]	叶放，吴勉华，程海波，等.国医大师周仲瑛教授《新型冠状病毒肺炎中医辨治方案》解读[J]. 南京中医药大学学报， 2020， 36(2):141-144.
[21]	张诗军，吴伟康.湿证病机“蒙蔽性”特点初探[J]. 中国中医基础医学杂志， 2008， 14(7):486-487.
[22]	黄帝内经素问[M].北京:人民卫生出版社，2005:45.
[23]	李中梓.医宗必读[M].呼和浩特：内蒙古人民出版社，2006:212.